Drug Approval | June 02, 2026
Bristol Myers Squibb wins EU approval for Opdivo-based frontline treatment in advanced hodgkin lymphoma
The approval is supported by results from the Phase 3 SWOG 1826 trial
The approval is supported by results from the Phase 3 SWOG 1826 trial
The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
Clearance marks major shift beyond chemotherapy
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
Veteran consumer health and FMCG strategist to lead preventive wellness and nutrition portfolio expansion through innovation and modern trade channels
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
Combined platform with 55+ centres aims to expand integrated maternity, fertility, neonatal and paediatric care across India
Subscribe To Our Newsletter & Stay Updated
